JAK2 inhibition sensitizes resistant EGFR-mutant lung adenocarcinoma to tyrosine kinase inhibitors

Lung adenocarcinomas with mutant epidermal growth factor receptor (EGFR) respond to EGFR-targeted tyrosine kinase inhibitors (TKIs), but resistance invariably occurs. We found that the Janus kinase (JAK)/signal transduction and activator of transcription 3 (STAT3) signaling pathway was aberrantly in...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Sci Signal
Autori principali: Gao, Sizhi P., Chang, Qing, Mao, Ninghui, Daly, Laura A., Vogel, Robert, Chan, Tyler, Liu, Shu Hui, Bournazou, Eirini, Schori, Erez, Zhang, Haiying, Brewer, Monica Red, Pao, William, Morris, Luc, Ladanyi, Marc, Arcila, Maria, Manova-Todorova, Katia, de Stanchina, Elisa, Norton, Larry, Levine, Ross L., Altan-Bonnet, Gregoire, Solit, David, Zinda, Michael, Huszar, Dennis, Lyden, David, Bromberg, Jacqueline F.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2016
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4950506/
https://ncbi.nlm.nih.gov/pubmed/27025877
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/scisignal.aac8460
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi